Regeneron Pharmaceuticals (REGN) said late Thursday its initial phase 1b trials data of linvoseltamab in combination with carfilzomib or bortezomib to treat refractory multiple myeloma showed a 90% objective response rate after a 15-month follow-up.
Almost 76% of patients achieved a complete response, the company said.
Adverse events were recorded in over 50% of the patients, while grade 3 adverse events included neutropenia, cytokine release syndrome, diarrhea, and thrombocytopenia. Infections developed in 91% of patients, and serious adverse events occurred in 83%.
The company will present trial data at the American Society of Clinical Oncology 2025 Annual Meeting on June 2.
Shares were down 2% in after-hours trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。